# A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

> **NCT07541079** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Early Breast Cancer

## Interventions

- **DRUG:** Giredestrant

## Key facts

- **NCT ID:** NCT07541079
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2032-06-30
- **Final completion:** 2034-06-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07541079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07541079, "A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07541079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*